AGÕæÈ˹ٷ½

BioVie Inc. (Nasdaq: BIVI) has filed Amendment No. 1 to its Form S-1 to complete a firm-commitment public offering that will roughly double the company’s share count and strengthen short-term liquidity.

• Size & structure: 1,456,310 Units (one post-split Class A share + one 5-year warrant) or, for investors breaching the 4.99 %/9.99 % ownership caps, an equal number of Pre-funded Units (one pre-funded warrant + one warrant). Gross proceeds at the assumed $10.30 price equal â‰� $15.0 million; net â‰� $13.8 million after 7 % underwriting fees and estimated offering costs (exact expenses not yet disclosed). Underwriters hold a 45-day over-allotment option for 15 % additional securities.
• Pricing metrics: Warrants strike at $12.875 (125 % of the assumed offer price) and will be listed on Nasdaq as “BIVIWâ€� (listing application pending). Pre-funded warrants exercise at $0.0001 and will not be listed.
• Capitalisation impact: Shares outstanding rise from 1,860,086 (6-30-25) to 3,316,396 before any warrant exercise—or 3,534,843 if the green-shoe is exercised in full—representing â‰� 78 % immediate dilution to existing holders. Potential dilution is greater when considering 960,098 legacy warrants (avg. $35.02 strike), 84,872 options (avg. $286.20 strike) and the new offering warrants (1.46 M) and banker warrants (â‰� 0.15 M).
• Reverse split executed: A 1-for-10 split became effective 7-7-25 to meet Nasdaq minimum bid requirements; all share figures reflect the split.
• Use of proceeds: “Working capital and general corporate purposesâ€� â€� presumed funding of ongoing clinical trials (bezisterim/NE3107 for Alzheimer’s, Parkinson’s and Long COVID; BIV201 terlipressin for ascites). No debt repayment or acquisition earmarked.
• Pipeline status: â€� Phase 3 AD study unblinded but undermined by cGCP violations at 15 sites, leaving an under-powered data set (81 mITT / 57 per-protocol patients). Company evaluating additional enrolment or a new Phase 3. â€� Phase 2b Parkinson’s study green-lit by FDA and began April 2025. â€� DOD-funded Phase 2 Long COVID trial (ADDRESS-LC) commenced May 2025; $13.1 M grant with $2.9 M reimbursed YTD. â€� BIV201 Phase 3 protocol being finalised after recent FDA guidance. Orphan Drug & Fast-Track designations remain in force.
• Litigation disclosure: Consolidated securities-fraud class action (In re BioVie Inc. Securities Litigation, D.Nev. No. 3:24-cv-00035) survived a motion to dismiss on 3-27-25 and is now in discovery; insurer deductible is $2 M.
• Risk highlights: continuing losses, need for repeated capital raises, substantial clinical and regulatory uncertainty, concentration of cash in one bank above FDIC limits, potential Nasdaq compliance issues if this offering is not deemed “public,â€� and broad indemnification/blank-check preferred provisions.

The filing positions BioVie to secure modest near-term funds but materially dilutes shareholders and does not address the more costly, pivotal trials still required for commercialization. Strategic success now hinges on swift resolution of AD data integrity questions, execution of new PD/Long-COVID trials, and eventual Phase 3 initiation for BIV201.

Lazydays Holdings, Inc. (Nasdaq: GORV) filed an 8-K disclosing three corporate-governance actions taken between 7 July and 9 July 2025.

• Indemnification agreements: The company executed new agreements with every board member and its Chief Administrative Officer. These contracts obligate Lazydays to advance expenses and fully indemnify the covered individuals to the maximum extent permitted by Delaware law, supplementing existing charter and by-law protections.
• Board appointment: Alexandre Zyngier (55) was appointed to fill a vacant board seat effective 7 July 2025 and is expected to join the Nominating & Governance Committee. Zyngier is Managing Director of Batuta Capital Advisors and holds multiple current and prior board positions across public and private companies.
• Leadership transition: On 9 July 2025 the board removed the “interimâ€� designation for Ronald K. Fleming, formally naming him Chief Executive Officer. The only change to Fleming’s 14 September 2024 employment agreement is the updated title, as documented in an amendment (Exhibit 10.2).

Exhibits include the form of indemnification agreement (10.1), the CEO employment-agreement amendment (10.2) and a related press release (99.1). No financial metrics, earnings guidance, or transactional details were provided. The filing primarily clarifies governance structure, risk allocation for directors/officers and solidifies executive leadership.

On July 8, 2025, ADT Inc. (ADT) director Sigal Zarmi automatically acquired 116 dividend equivalent units that accrued on previously granted restricted stock units (RSUs). The dividend equivalents were calculated using ADT’s closing share price on that date and will vest on May 21, 2026 alongside the underlying RSUs. After the transaction, Zarmi directly holds 81,072 shares of ADT common stock. No common-stock sales or derivative transactions were reported.

The filing represents a routine, non-cash adjustment rather than a discretionary market purchase. Given the small number of shares involved (<0.1% of Zarmi’s holdings) and the automatic nature of the accrual, the event is considered immaterial to ADT’s share float and does not signal a strategic shift. Investors are unlikely to view the transaction as a meaningful indicator of insider sentiment.

Lazydays Holdings, Inc. (Nasdaq: GORV) has approved and scheduled a 1-for-30 reverse stock split of its common shares, to be effective at 5:00 p.m. ET on July 7, 2025. Trading on a split-adjusted basis will begin July 14, 2025 under the unchanged ticker “GORVâ€� and a new CUSIP (52110H209).

The split was authorized by shareholders at the July 3, 2025 annual meeting and subsequently fixed by the Board to bring the share price back above Nasdaq’s $1.00 minimum bid required in Listing Rule 5550(a)(2). Every 30 outstanding shares will automatically combine into one new share. No cash will be paid for fractional shares; instead, fractional positions will be rounded up to the nearest whole share, slightly increasing total shares outstanding by an immaterial amount.

• Capital structure: The action does not change the number of authorized shares or the $0.0001 par value.
• Derivative securities: All outstanding options, warrants and share-based plan reserves will be proportionally adjusted.
• Ownership impact: Percentage ownership for existing holders remains unchanged other than de-minimis rounding.
• Regulatory motive: The split aims to preserve the Company’s Nasdaq listing status; no operational or balance-sheet changes are involved.
• Disclosure: Details were announced via press release (Exhibit 99.1) and filed on Form 8-K, Item 8.01.

Management’s decision signals an urgent need to elevate the market price after prolonged trading below $1.00. While necessary to avoid delisting, such high-ratio reverse splits can be perceived negatively by the market because they often accompany weak share-price performance. Investors should monitor liquidity, post-split bid-price compliance, and any fundamental initiatives designed to improve operating results beyond the mechanical share consolidation.

Under Armour, Inc. (ticker: UAA/UA) has filed a Form 4 indicating that board member Mohamed El-Erian acquired 3,338.28 Class C common shares on 07/01/2025.

The shares were issued at $0.00 under the company’s Fiscal Year 2025 Non-Employee Director Compensation Plan, meaning the award represents deferred stock units in lieu of cash director fees rather than an open-market purchase.

After the grant, El-Erian’s direct holdings stand at 172,457.93 Class C shares and 11,650 Class A shares. No derivative positions were reported and no shares were sold.

This filing reflects routine board compensation and is not indicative of a strategic share-accumulation program. The transaction is immaterial relative to Under Armour’s total share count and should have negligible impact on valuation or governance dynamics.

Lazydays Holdings, Inc. (Nasdaq: GORV) filed an 8-K to disclose two binding agreements signed on 18 June 2025 with Texas-based Ron Hoover Companies, Inc..

1. Asset Purchase Agreement
� Seller: Lazydays RV of Oklahoma, LLC (indirect subsidiary)
� Assets: substantially all operating assets of the Claremore, Oklahoma RV dealership at 24655 S. Highway 66.
� Consideration: � US$2.1 million for goodwill, F,F&E and parts, plus additional cash at closing for new & used RV inventory and service work-in-process (amounts to be calculated based on actual inventories).
� Closing conditions: customary reps & warranties; operation in ordinary course until close; repayment of debt secured by the purchased assets from sale proceeds.
� Termination: mutual consent, injunction, non-closing after 1 Aug 2025, or specified breaches/misrepresentations.

2. AGÕæÈ˹ٷ½ Estate Purchase Agreement
â€� Seller: LD AGÕæÈ˹ٷ½ Estate, LLC (indirect subsidiary).
� Property: underlying dealership real estate.
� Consideration: � US$7 million cash, subject to customary adjustments.
� Automatic termination if the Asset Purchase Agreement is terminated.

The combined transactions could generate � US$9.1 million in gross proceeds before inventory adjustments and debt payoff. A press release announcing the agreements was issued on 24 June 2025 (Exhibit 99.1). No earnings data or intended use of proceeds were provided.

Form Type: 4 � Statement of Changes in Beneficial Ownership

On 06/18/2025, Stitch Fix, Inc. (SFIX) Chief Product & Technology Officer Anthony Bacos reported a single insider transaction. The company withheld 26,636 Class A common shares to satisfy tax liabilities triggered by the vesting of restricted stock units. The transaction was coded “F,� confirming it was strictly a tax-withholding event, not an open-market sale. Shares were valued at $3.87 each, representing an implied cash value of roughly $103.3 thousand.

After the transaction, Bacos� direct beneficial ownership is 859,966 shares, demonstrating continued substantial alignment with shareholder interests. No derivative securities were exercised or disposed, and the filing does not reference a Rule 10b5-1 trading plan.

• The disposition equals about 3.1 % of Bacosâ€� post-transaction holdings and is considered routine.
• The event does not alter Stitch Fix’s capital structure or float in a material way and is therefore viewed as neutral for market sentiment.

Lazydays Holdings (GORV) has announced its 2025 Annual Meeting of Stockholders to be held virtually on July 3, 2025. The meeting will address several significant proposals:

• Election of Susan Scarola as Class A director until 2028
• Ratification of RSM US LLP as independent auditor
• Advisory vote on executive compensation
• Approval to increase 2018 Long-Term Incentive Plan shares by 12 million
• Approval of a reverse stock split at a ratio between 1-for-2 and 1-for-30

As of the June 13, 2025 record date, 110,294,164 shares were outstanding. Shareholders can vote online, by phone, or mail. The Board recommends voting "FOR" all proposals. Notably, broker non-votes will not count for most proposals except the auditor ratification. The reverse stock split proposal represents a significant potential change to the company's capital structure.